Insmed Inc’s recently made public that its Director SHAROKY MELVIN MD unloaded Company’s shares for reported $1.22 million on Aug 12 ’25. In the deal valued at $121.58 per share,10,000 shares were sold. As a result of this transaction, SHAROKY MELVIN MD now holds 290,616 shares worth roughly $37.14 million.
Then, Schaeffer Orlov S Nicole bought 10,000 shares, generating $1,273,070 in total proceeds.
Before that, ALFRED ALTOMARI bought 13,600 shares. Insmed Inc shares valued at $1,654,338 were divested by the Former Affiliate at a price of $121.64 per share.
Morgan Stanley downgraded its Insmed Inc [INSM] rating to an Equal-weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. RBC Capital Mkts began covering INSM with “an Outperform” recommendation on February 25, 2025. Truist started covering the stock on April 23, 2024. It rated INSM as “a Buy”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock jump 0.04% to $127.8. Over the last five days, the stock has gained 16.66%. Insmed Inc shares have risen nearly 67.32% since the year began. Nevertheless, the stocks have risen 85.11% over the past one year. While a 52-week high of $128.48 was reached on 08/14/25, a 52-week low of $60.40 was recorded on 04/09/25.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 125.55, which if violated will result in even more drops to 123.29. On the upside, there is a resistance level at 129.03. A further resistance level may holdings at 130.25.
How much short interest is there in Insmed Inc?
A steep rise in short interest was recorded in Insmed Inc stocks on 2025-07-31, dropping by -0.26 million shares to a total of 9.54 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 9.8 million shares. There was a decline of -2.72%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 15, 2024 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $42 price target.
